|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Autier P, Boniol M, La Vecchia C, Vatten
L, Gavin A, Héry C and Heanue M: Disparities in breast cancer
mortality trends between 30 European countries: Retrospective trend
analysis of WHO mortality database. BMJ. 341:c36202010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee J and Gollahon L: Nek2-targeted ASO or
siRNA pretreatment enhances anticancer drug sensitivity in
triple-negative breast cancer cells. Int J Oncol. 42:839–847.
2013.PubMed/NCBI
|
|
6
|
Berrada N, Delaloge S and André F:
Treatment of triple-negative metastatic breast cancer: Toward
individualized targeted treatments or chemosensitization? Ann
Oncol. 21(Suppl 7): vii30–vii35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pylayeva-Gupta Y, Grabocka E and Bar-Sagi
D: RAS oncogenes: Weaving a tumorigenic web. Nat Rev Cancer.
11:761–774. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bos JL, Rehmann H and Wittinghofer A: GEFs
and GAPs: Critical elements in the control of small G proteins.
Cell. 129:865–877. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McLaughlin SK, Olsen SN, Dake B, De Raedt
T, Lim E, Bronson RT, Beroukhim R, Polyak K, Brown M, Kuperwasser
C, et al: The RasGAP gene, RASAL2, is a tumor and metastasis
suppressor. Cancer Cell. 24:365–378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Y, Deng Y, Ji Z, Liu H, Liu Y, Peng H,
Wu J and Fan J: Identification of thyroid carcinoma related genes
with mRMR and shortest path approaches. PLoS One. 9:e940222014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang Y, Zhao M, Xu H, Wang K, Fu Z, Jiang
Y and Yao Z: RASAL2 down-regulation in ovarian cancer promotes
epithelial-mesenchymal transition and metastasis. Oncotarget.
5:6734–6745. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li N and Li S: RASAL2 promotes lung cancer
metastasis through epithelial-mesenchymal transition. Biochem
Biophys Res Commun. 455:358–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feng M, Bao Y, Li Z, Li J, Gong M, Lam S,
Wang J, Marzese DM, Donovan N, Tan EY, et al: RASAL2 activates RAC1
to promote triple-negative breast cancer progression. J Clin
Invest. 124:5291–5304. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Yang P and Wang XF:
Microenvironmental regulation of cancer metastasis by miRNAs.
Trends Cell Biol. 24:153–160. 2014. View Article : Google Scholar
|
|
16
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valastyan S, Reinhardt F, Benaich N,
Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and
Weinberg RA: A pleiotropically acting microRNA, miR-31, inhibits
breast cancer metastasis. Cell. 137:1032–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Sempere LF, Ouyang H, Memoli VA,
Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al:
MicroRNA-31 functions as an oncogenic microRNA in mouse and human
lung cancer cells by repressing specific tumor suppressors. J Clin
Invest. 120:1298–1309. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu J, Wang F, Yang GH, Wang FL, Ma YN, Du
ZW and Zhang JW: Human microRNA clusters: Genomic organization and
expression profile in leukemia cell lines. Biochem Biophys Res
Commun. 349:59–68. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee DY, Jeyapalan Z, Fang L, Yang J, Zhang
Y, Yee AY, Li M, Du WW, Shatseva T and Yang BB: Expression of
versican 3′-untranslated region modulates endogenous microRNA
functions. PLoS One. 5:e135992010. View Article : Google Scholar
|
|
24
|
Shen S, Yue H, Li Y, Qin J, Li K, Liu Y
and Wang J: Upregulation of miR-136 in human non-small cell lung
cancer cells promotes Erk1/2 activation by targeting PPP2R2A.
Tumour Biol. 35:631–640. 2014. View Article : Google Scholar
|
|
25
|
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J
and Li M: MiR-136 promotes apoptosis of glioma cells by targeting
AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: FEMME Consortium: Triple-negative breast cancer:
Present challenges and new perspectives. Mol Oncol. 4:209–229.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carey L, Winer E, Viale G, Cameron D and
Gianni L: Triple-negative breast cancer: Disease entity or title of
convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aysola K, Desai A, Welch C, Xu J, Qin Y,
Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, et al: Triple
negative breast cancer: An overview. Hereditary Genet. 2013(Suppl
2): 20132013.
|
|
30
|
Zhao H, Liu S, Wang G, Wu X, Ding Y, Guo
G, Jiang J and Cui S: Expression of miR-136 is associated with the
primary cisplatin resistance of human epithelial ovarian cancer.
Oncol Rep. 33:591–598. 2015.
|
|
31
|
Wu H, Liu Q, Cai T, Chen YD, Liao F and
Wang ZF: MiR-136 modulates glioma cell sensitivity to temozolomide
by targeting astrocyte elevated gene-1. Diagn Pathol. 9:1732014.
View Article : Google Scholar : PubMed/NCBI
|
